The pharmaceutical industry today spends far more on research and development, but produces fewer new molecules, than it did 20 years ago. That shortfall in pipeline innovation leaves drug makers unable to capitalize on the rising global demand for new medicines.
A deficit of in-house talent with the special mix of skills, intuition and broad experience is the most common impediment to research and development progress. Like a rusty boat anchor, archaic cultural norms can be a major roadblock to innovation and insight for complex and timely decision-making. The most successful pharmaceutical and biologics companies are nimble, constantly adjusting the way they operate; they evolve and innovate to create new therapies to meet the world’s medical needs.
The Evanston Group’s consultants are among the top biopharmaceutical experts across a wide range of therapeutic areas. After devoting their entire professional lives to innovation in the search for medicines that prolong and improve human life, they command seasoned expertise within their fields. From pre-clinical bench science and clinical trial management to database management, medical writing and program management teams, The Evanston Group’s consultants deliver value from the substantial investments required to develop safe and effective medicines.
One major pharmaceutical company was in clinical trials in 80 locations around the world for a compound to treat pediatric renal failure, a rare disease state. The clinical trial was tricky and beset by major safety concerns. With no time to waste, the company needed a supervising clinical operations manager with extensive rare disease clinical trial experience. The position required a self-starter with the ability to hit the ground running.
The Evanston Group quickly delivered a consultant whose decades of experience with complex and difficult human trials in rare disease states matched the drug company’s requirement. The consultant spent four years on three separate clinical trial studies, worked hand-in-hand with the drug company’s staff, and successfully completed the final-stage clinical trial on time. The company is now preparing a submission for final Food and Drug Administration marketing approval.
Another successful Evanston Group delivery was with a Fortune 500 pharmaceutical leader who required a project team of experts to manage executive communications for the rollout of a global R&D organization restructuring. Decisive, considerate communication was critical to instill confidence in the revamped R&D organization’s plan to deliver innovation and clinical productivity gains.
C-suite executives and stakeholders throughout the R&D organization met monthly with The Evanston Group’s Team, who created newsletters, presentations, emails and other collateral, as well as hosted a series of town hall meetings featuring presentations about the new organizational structure and fundamental changes to the nature of day-to-day work. This collaborative approach achieved all desired control targets and saved the company $1.9 million annually.
